Verona Pharma plc
17
2
2
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 17 trials
100.0%
+13.5% vs industry average
18%
3 trials in Phase 3/4
73%
11 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
Role: lead
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
Role: lead
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
Role: lead
A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease
Role: lead
Effect of Ensifentrine Treatment on CAT Score
Role: lead
A Study of RPL554 in Patients With Cystic Fibrosis
Role: lead
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Role: lead
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
Role: lead
Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler
Role: lead
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
Role: lead
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
Role: lead
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
Role: lead
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Role: lead
The Effects of RPL554 in Addition to Tiotropium in COPD Patients
Role: lead
Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients
Role: lead
The Effects of RPL554 on Top of Standard COPD Reliever Medications
Role: lead
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects
Role: lead
All 17 trials loaded